Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity		ABN/ARSN	
Sigma Pharmaceuticals Limited	15 088 417 403		
We (the entity) give ASX the following	ng information.		
Information about buy-back			
Type of buy-back	On-market buy-back		
Date Appendix 3C was given t ASX	13 September 2012 (Associated Appendix 2014)	3D dated 2 October	
		o which acceptances Previous day	
Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	Before previous day 109,686,102		

Before previous day	Previous day

5 If buy-back is an on-market buyback

	Highest \$0.8525	price	paid:	Highest price paid: \$0.8300		
	Lowest	price	paid:	Lowest price paid: \$0.8200		
	\$0.5600	price	paiu.	Highest price allowed under rule 7.33: \$0.8301		
1						

How many shares/units may still be bought back?

6	If the company/trust has disclosed						
	an	intention	to	buy	back	a	
	max	kimum num	ber o	of shar	es/unit	s –	
	the	remaini	ng	num	ber	of	
	shar	res/units to	be b	ought	back		

8,869,101				

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.

== == == == ==

2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 22 July 2015

(Director/Company secretary)

Print name: Sue Morgan